Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen

An isolated polynucleotide sequence comprising the nucleic acid sequence of SEQ.ID.NO.2.

An isolated polypeptide comprising the amino acid sequence of SEQ.ID.NO.3.

An isolated polypeptide comprising the amino acid sequence of SEQ.ID.NO.4.

An isolated polypeptide comprising the amino acid sequence of SEQ.ID.NO.59.

An expression vector comprising a nucleic acid sequence of SEQ.ID.NO.1.

An expression vector comprising a nucleic acid sequence of SEQ.ID.NO.2.

An expression vector comprising a polynucleotide encoding signal sequence, a polynucleotide encoding at least one epitope of human telomerase reverse transcriptase (hTRT), a polynucleotide encoding a cell binding element and a polynucleotide encoding a dendritic cell receptor, all operatively linked.

An expression vector comprising a polynucleotide encoding signal sequence, a first polynucleotide sequence encoding at least one epitope of hTRT, a second sequence polynucleotide encoding at least one epitope of hTRT, a polynucleotide sequence encoding a cell binding element and a polynucleotide sequence encoding a dendritic cell receptor, all operatively linked.

An expression vector comprising a two transgenes, wherein the first and second transgene comprises a promoter polynucleotide sequence, a polynucleotide encoding signal sequence, a polynucleotide sequence encoding at least one epitope of hTRT, a polynucleotide sequence encoding a cell binding element, and a polynucleotide sequence encoding a dendritic cell receptor, all operatively linked.

A method of eliciting an immune response directed against an antigen comprising the step of administering to a patient a peptide selected from the group consisting of SEQ.ID.NO.17, SEQ.ID.NO.18, SEQ.ID.NO.19, SEQ.ID.NO.20, SEQ.ID.NO.21, SEQ.ID.NO.22, SEQ.ID.NO.23, SEQ.ID.NO.24, SEQ.ID.NO.25, SEQ.ID.NO.26, SEQ.ID.NO.27, SEQ.ID.NO.59, SEQ.ID.NO.62,SEQ.ID.NO.77, SEQ.ID.NO.89, SEQ.ID.NO.90, SEQ.ID.NO.91, SEQ.ID.NO.92, SEQ.ID.NO.93 and SEQ.ID.NO.94.

A method of eliciting an immune response directed against an antigen comprising the step of administering to a subject a composition comprising SEQ.ID.NO.3 or SEQ.ID.NO.4.

A method of treating a hyperproliferative disease comprising the step of administering transduced antigen presenting cells to a subject via a parenteral route.

A method of treating a hyperproliferative disease comprising the step of administering to a subject an expression vector with a pharmaceutical acceptable carrier, wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an at least one epitope of hTRT, and a polynucleotide encoding a cell binding element and a polynucleotide sequence encoding a dendritic cell receptor, all operatively linked.

A method of treating a hyperproliferative disease comprising administering to a subject a hTRT specific peptide with a pharmaceutical acceptable carrier, wherein said peptide binds to a MHC-II receptor.

A method of treating a hyperproliferative disease comprising administering to a subject a hTRT specific peptide with a pharmaceutical acceptable carrier, wherein said peptide binds to a MHC-I and MHC-II receptor.